人脑胶质瘤组织中耐药相关基因MGMT、TopoⅡ的表达分析

doi:10.3969/j.issn.1671-2587.2020.03.020

临床输血与检验 ›› 2020, Vol. 22 ›› Issue (3): 304-308.DOI: 10.3969/j.issn.1671-2587.2020.03.020

人脑胶质瘤组织中耐药相关基因MGMT、TopoⅡ的表达分析

吉子拉洛, 杨国平, 姚曾亚

615000 西昌市凉山州中西医结合医院神经外科

收稿日期:2018-12-20 出版日期:2020-06-20 发布日期:2020-06-13
作者简介:吉子拉洛（1968-）,男,彝族,四川凉山人,副主任医师,学士,主要从事神经外科相关疾病诊治方面研究,（E-mail）y12512515@sina.com。

Expression of Drug Resistance Related Genes MGMT and TopoII in Human Glioma

JIZI La-luo, YANG Guo-ping, YAO Zeng-ya

Neurosurgery, Liangshan Hospital of Integrated Traditional Chinese and Western Medicine, Xichang 615000

Received:2018-12-20 Online:2020-06-20 Published:2020-06-13

摘要/Abstract

摘要： 目的探究人脑胶质瘤组织中耐药相关基因O⁶-甲基鸟嘌呤-DNA-甲基转移酶（MGMT）、DNA拓扑异构酶Ⅱ（TopoⅡ）的表达及意义。方法采用免疫组化方法检测96例脑胶质瘤组织及30例正常脑组织MGMT及TopoⅡ的表达,比较不同组织基因表达差异,分析脑胶质瘤组织基因表达与临床资料及预后的关系。结果脑胶质瘤组织中,MGMT及TopoⅡ表达阳性率分别为57.29%及36.45%;正常脑组织MGMT及TopoⅡ基因表达阳性率分别为6.33%及3.33%;差异有统计学意义（P<0.05）;TopoⅡ表达阳性率随肿瘤恶性程度增加而增加（P<0.05）;入组脑胶质瘤病例中79人获得随访,随访时间为3~32个月,MGMT及TopoⅡ表达阴性患者生存时间均长于表达阳性患者,差异有统计学意义（P<0.05）。结论人脑胶质瘤组织中MGMT及TopoⅡ有较高的阳性表达率,其中TopoⅡ表达与脑胶质瘤恶性程度相关,两者表达情况均与患者预后相关。

关键词: 脑胶质瘤, O⁶-甲基鸟嘌呤-DNA-甲基转移酶, DNA拓扑异构酶Ⅱ, 免疫组化

Abstract: Objective To investigate the expression and significance of drug resistance related genes O⁶-methylguanine-DNA-methyltransferase (MGMT) and DNA topoisomerase II (TopoII) in human glioma. Methods The expression of MGMT and TopoII in 96 cases of glioma tissues and 30 cases of normal brain tissues was detected by immunohistochemical staining method. The expression of genes was compared between different tissues, and the relationship between the expression of genes in glioma and clinical data and prognosis was analyzed. Results The positive expression rates of MGMT and TopoII in glioma tissues were 57.29% and 36.45%, respectively while in normal brain tissues were 6.33% and 3.33%, respectively (P<0.05). The expression rate of TopoII increased with the degree of tumor malignancy (P<0.05). 79 patients with gliomas were followed up for 3~32 months. The survival time of patients with negative of MGMT and TopoII was longer than that of patients with expression of MGMT and TopoII (P<0.05). Conclusion The expression rates of MGMT and TopoII are high in human glioma. The expression of TopoII is related to the malignant degree of glioma, and the expression of the two genes is related to the prognosis of patients.

Key words: Glioma, O⁶-methylguanine-DNA-methyltransferase, DNA topoisomerase II, Immunohistochemistry

中图分类号:

R739.4

吉子拉洛, 杨国平, 姚曾亚. 人脑胶质瘤组织中耐药相关基因MGMT、TopoⅡ的表达分析[J]. 临床输血与检验, 2020, 22(3): 304-308.

JIZI La-luo, YANG Guo-ping, YAO Zeng-ya. Expression of Drug Resistance Related Genes MGMT and TopoII in Human Glioma[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(3): 304-308.

参考文献

[1] 林昌海,李丽仙,冉静,等.脑胶质瘤血液循环肿瘤标志物研究进展[J].重庆医学,2016,45(30):4293-4296.
[2] 陈海南,莫立根,邓腾.脑胶质瘤神经分子病理指标在临床治疗及预后评估中的作用[J].中国组织工程研究,2016,4(A02):288-289.
[3] 李宁,余琦,孙洋,等.非小细胞肺癌多耐药基因产物(P-gp)表达与多种预后因素的关系[J].标记免疫分析与临床,2010,17(5):318-320.
[4] 雷媛媛,张建伟,唐波,等.O-6-甲基鸟嘌呤-DNA甲基转移酶在顺铂激活的胃癌细胞自噬中的作用[J].第三军医大学学报,2018,40(4):290-295.
[5] 李珂珂,童创,王建国,等.TopoⅡα和Ki67在浸润性乳腺癌中的表达及其临床意义[J].安徽医学,2016,37(1):18-21.
[6] Rousseau A,Mokhtari K,Duyckaerts C.The 2007 WHO classification of tumors of the central nervous system-what has changed?[J]. Curr Opin Neurol, 2008,21(6):720-727.
[7] 孙晓琴,易山,牛香莲,等.miRNA参与肿瘤基因表达调控研究进展[J].现代生物医学进展,2016,16(8):1551-1554.
[8] 杨洁,袁江伟,王玉祥,等.MGMT基因甲基化水平与恶性胶质瘤细胞对烷化剂耐药性的相关性[J].中国老年学杂志,2015,35(7):1949-1950.
[9] Amatu A,Barault L,Moutinho C,et al.Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer[J].Ann Oncol,2016,27(6):1062-1067.
[10] 付文婷,王科燕,宋春莉,等.2012~2014年我院抗肿瘤药物超说明书用药调查分析与合理性评价[J].中国医药导报,2016,13(8):146-149.
[11] 苏赓,梁科庆.MGMT和galectin-3异常调控在结肠腺癌中的研究进展[J].中国医药导报,2016,13(17):33-35.
[12] 李靖远,许在华.异柠檬酸脱氢酶-1突变与O6-甲基鸟嘌呤-DNA-甲基转移酶启动子甲基化在高级别胶质瘤中表达相关性及对预后影响研究[J].临床军医杂志,2017,45(10):1085-1086.
[13] 杜希越,薛晓英,盖晓惠,等.脑胶质瘤分子标志物IDH1R132突变、MGMT和Ki-67与病理分级及预后关系的研究[J].安徽医科大学学报,2017,52(3):417-421.
[14] 郭恒照,汤忠明,朱亚平,等.O^6-甲基鸟嘌呤-DNA甲基转移酶在恶性脑胶质瘤组织中的表达及意义[J].中国肿瘤临床与康复,2017,24(12):1435-1438.
[15] 徐伟铭,杨佩浓,袁秋琦.胃癌组织中Ki67和TOPOⅡα的表达及其与临床病理参数的关系[J].中国中西医结合消化杂志,2016,24(4):278-280.
[16] Wenxiang L I,Wei J,Senyan H U,et al.Changes of Topo-ⅡProtein in Patients with Breast Cancer before and after Neoadjuvant Chemotherapy and Its Guiding Significance for Postoperative Chemotherapy[J]. Practical Journal of Cancer,2017,32(12):1918-1921.
[17] 陈寅波,刘卓,钱俊,等.P53与Ⅱ型拓扑异构酶及多重耐药相关蛋白在合并慢性血吸虫病结直肠癌组织中的表达[J].中华消化外科杂志,2016,15(8):815-819.
[18] 洪杨,尚超,薛一雪,等.人脑胶质瘤中DNA拓扑异构酶-Ⅱα的表达及其对胶质瘤U87MG细胞凋亡的影响[J].中国现代医学杂志,2013,23(30):27-30.

人脑胶质瘤组织中耐药相关基因MGMT、TopoⅡ的表达分析

Expression of Drug Resistance Related Genes MGMT and TopoII in Human Glioma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们